Company

Orphan Drug Designation for DK0112-01, the human peptide Thymopentin, for the treatment of Sarcoidosis granted on 02/04/2011 (FDA n.10/3300)

Orphan Drug Status designation for DK0210-01 in Chronic Beryllium Disease granted on 02/09/2010

Ruggero Gramatica has been appointed as the new CEO of mondoBIOTECH holding AG. Fabio Cavalli founder and former CEO, takes on the role of Executive Chairman and will set the strategy and vision for the company and lead on business development opportunities, working side by side with Ruggero.

WR Hambrecht + Co. has assigned a team of analysts, market strategists, and senior executives, led by Elizabeth Hambrecht herself to work with officers and board members of mondoBIOTECH holding AG.

Lung Rx, a fully owned subsidiary of United Therapeutics Corporation, and mondoBIOTECH finalized a global strategic partnership focused on the development of Aviptadil for a range of indications, as for example PAH, Sarcoidosis, Idiopathic Pulmonary Fibrosis (IPF) and Acute Respiratory Distress Syndrome (ARDS). 

Bachem will provide to mondoBIOTECH its comprehensive know how on peptides and its longstanding experience in the manufacture of peptides and finished pharmaceutical products.

mondoBIOTECH holding AG went public today on the SIX Swiss Exchange in Zürich under the ticker tape symbol RARE. We are deeply grateful to all the investors who have embraced mondoBIOTECH's philosophy, business model, and commitment to assist the community of patients suffering from rare and neglected diseases.

President of the Swiss Cancer League Prof. Thomas Cerny, Kantonsspital of St. Gallen, joins the Board of Directors of mondoBIOTECH holding AG

MondoBIOTECH and 23andMe partner to advance research on rare diseases. We partnered with 23andMe (genetic company invested by Google, Inc. and other investors) to advance genetic research for patients in rare diseases

mondoBIOTECH receives the Swiss Innovation Award 2008 from the Central Swiss Chamber of Commerce

Beneficial effects of inhaled Aviptadil in patients with chronic pulmonary hypertension published in The European Respiratory Journal (2008 Nov;32(5):1289-94)

mondoBIOTECH is granted the leasehold on the former Capuchin monastery in Stans (Switzerland) as headquarter and research center

mondoBIOTECH filed patent applications for more than 300 medicinal product candidates for the treatment of rare diseases

Lung Rx, a fully owned subsidiary of United Therapeutics Corporation, and mondoBIOTECH sign a transatlantic strategic partnership agreement for developing medicaments for the treatment of rare diseases

Business alliance with IFE Europe GmbH, a company owned by Pierrel S.p.A., for clinical study management

Agreement with Southern Research Institute for biological screening of 312 peptides.

mondoBIOTECH started campus educations on rare diseases for networking and exchange information with the medical Community for rare diseases

mondoBIOTECH selected as Technology Pioneer 2008 by the World Economic Forum

Orphan Medicinal Product Designation for Aviptadil in Sarcoidosis (EU/3/07/473)

mondoBIOTECH selected as Best Innovator 2007

Chief Business Architect Fabio Cavalli Start-up Swiss Entrepreneur of the Year 2006

Collaboration and licensing agreement with Biogen Idec for Aviptadil in PAH

EMEA Orphan Medicinal Product Designation for Aviptadil in Acute Lung Injury (ALI) 
(EU/3/06/395) received 28/08/2006

Agreement with Nebu-Tec for inhalative treatments in orphan diseases

Official opening of the Hardhof Basel, mondoBIOTECH’s Headquarters

Business Alliance with Quintiles for management of mondoBIOTECH’s clinical trials

Exclusive access to Bachem Peptide Library

Parallel Advice Protocol Review for Aviptadil in PAH Phase III

Prof. Dr. Robert Huber, Nobel laureate, appointed to mondoBIOTECH Board of Directors

Winner of the Swiss Life Sciences Prize 2005

Orphan drug status designation for Aviptadil in granted on 01/06/2005

Interferon gamma patent (EP 0 795 332 B1) for: “Medical use of Gamma Interferon in Interstitial Lung Diseases” granted on 01/06/2005

Orphan drug status designation (EU/3/05/281) for Interferon gamma in IPF granted o 30/05/2005

Collaboration agreement for production & supply of Thymopentin for studies in different orphan indications

Orphan drug status designation for Aviptadil in PAH granted on 22/02/2005

mondoBIOTECH’s opens offices in Basel, Switzerland

Exclusive licensing agreement for manufacturing Aviptadil for studies in different orphan indications

Orphan Drug Status for Aviptadil in PAH and CTEPH EU/3/03/173 granted on 23/12/2003

Aviptadil results in PPH published

Out-Licensing agreement for IFN-γ in IPF and Asthma

mondoBIOTECH is started immediately after the human genome is deciphered